01 1Shilpa Pharma Lifesciences Limited
01 1Busulfan
01 1India
Registration Number : 230MF10027
Registrant's Address : Shilpa House, #12-6-214/A1, Hyderabad Road, Raichur-584135, Karnataka, India
Initial Date of Registration : 2018-02-15
Latest Date of Registration : 2018-02-15
85
PharmaCompass offers a list of Busulfan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Busulfan manufacturer or Busulfan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Busulfan manufacturer or Busulfan supplier.
A CB 2041 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CB 2041, including repackagers and relabelers. The FDA regulates CB 2041 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CB 2041 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CB 2041 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A CB 2041 supplier is an individual or a company that provides CB 2041 active pharmaceutical ingredient (API) or CB 2041 finished formulations upon request. The CB 2041 suppliers may include CB 2041 API manufacturers, exporters, distributors and traders.
click here to find a list of CB 2041 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CB 2041 Drug Master File in Japan (CB 2041 JDMF) empowers CB 2041 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CB 2041 JDMF during the approval evaluation for pharmaceutical products. At the time of CB 2041 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CB 2041 suppliers with JDMF on PharmaCompass.
We have 1 companies offering CB 2041
Get in contact with the supplier of your choice:
